

Drug Delivery in Central Nervous System Disorders

Technologies, Companies and Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

June 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training with specialist's qualifications. His personal experience includes some of the technologies mentioned in this report. He received graduate training in both Europe and USA, and has held academic positions in several countries. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK and has been working in the biotechnology/biopharmaceuticals industry for several years. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, neurology, and pharmaceuticals.

Prof. Jain has edited "Drug Delivery to the Central Nervous System (Springer/Humana 2010)", and "Drug Delivery Systems", 2nd ed (Springer/Humana 2014)". Most recently he has edited "Applied Neurogenomics" (Springer 2015). Books authored by him include "Handbook of Nanomedicine (Springer 2008, Chinese edition, Peking University Press 2011, 3rd ed Springer 2017)", "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015)", "Handbook of Biomarkers (Springer 2010; Chinese edition, Chemical Industry Press, 2016, 2nd ed Springer 2017)", "Handbook of Neuroprotection (Springer 2011)", "Drug-induced Neurological Disorders, 3rd ed (Hogrefe 2011)", "Applications of Biotechnology in Neurology (Springer 2013)", and "Applications of Biotechnology in Oncology (Springer 2014)".

A B O U T T H I S R E P O R T

The original report on Drug Delivery in CNS Diseases by the author was published by Decision Resources Inc in 2000 as an enlargement of the chapter on this topic in his report on Drug Delivery Technologies (1998), which was also published by Decision Resources. The second edition was rewritten and published at Jain PharmaBiotech in 2004 and is being constantly rewritten since then.

**June 2018 (constantly updated since first edition published in 2000 by Decision Resources Inc)
Copyright © 2018 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	16
1. Basics of Drug Delivery to the Central Nervous System	18
Introduction	18
Historical evolution of drug delivery for CNS disorders.....	18
Neuroanatomical and neurophysiological basis of drug delivery.....	19
The cerebrospinal fluid	19
The lymphatic drainage system of the brain	20
The extracellular space in the brain	20
Neurotransmitters.....	21
Extracellular vesicles as drug delivery vehicles	23
Neuropharmacology relevant to drug delivery.....	23
Introduction to neuropharmacology.....	23
Pharmacokinetics.....	23
<i>Absorption and distribution of drugs</i>	<i>23</i>
<i>Drug metabolism and elimination.....</i>	<i>24</i>
Pharmacodynamics	24
<i>Receptors</i>	<i>24</i>
Sites of drug action in the CNS	24
<i>Receptors coupled to guanine nucleotide binding proteins</i>	<i>25</i>
<i>Acetylcholine receptor channels</i>	<i>25</i>
<i>Dopamine receptors.....</i>	<i>25</i>
<i>GABA receptor channels.....</i>	<i>26</i>
<i>Glutamate receptor channels.....</i>	<i>26</i>
<i>Non-competitive NMDA antagonists.....</i>	<i>26</i>
<i>Serotonin receptors.....</i>	<i>27</i>
<i>G-protein coupled receptors</i>	<i>27</i>
In vivo study of drug action in the CNS in human patients	27
<i>Electroencephalography.....</i>	<i>27</i>
<i>Brain imaging.....</i>	<i>28</i>
Chronopharmacology as applied to the CNS	28
Role of drug delivery in personalized therapy of CNS disorders	29
2. Blood Brain Barrier	30
Introduction	30
Features of the blood-brain barrier relevant to CNS drug delivery.....	30
The neurovascular unit	30
Functions of the BBB	31
<i>BBB as an anatomical as well as physiological barrier</i>	<i>31</i>
<i>BBB as a biochemical barrier</i>	<i>32</i>
<i>Glucose transporters at the BBB</i>	<i>32</i>
Role of shear stress on development of BBB.....	33
Genomics of BBB	33
Proteomics of BBB.....	34
Other neural barriers	34
Blood-cerebrospinal fluid barrier	34
Blood nerve barrier	35
Blood-retinal barrier	35
Blood-labyrinth barrier	35
Passage of substances across the blood-brain barrier	35
Transporters localized in the BBB	36
<i>Adenosine carrier.....</i>	<i>37</i>
<i>Amino acid transporters.....</i>	<i>37</i>
<i>Efflux transport systems</i>	<i>38</i>
<i>Glucose transporter.....</i>	<i>39</i>
<i>Ionic transporter.....</i>	<i>39</i>
BBB-specific enzymes.....	40
Receptor-mediated transcytosis	40
Lysophosphatidic acid-mediated increase in BBB permeability	41
Folate transport system	41
Transferrin receptor	41
Molecular biology of the BBB	41
Transport of peptides and proteins across the BBB	42
<i>Passage of leptin across the BBB.....</i>	<i>42</i>
<i>Passage of cytokines across the BBB</i>	<i>42</i>
<i>Passage of hormones across the BBB</i>	<i>43</i>
<i>Passage of enzymes across the BBB</i>	<i>43</i>

Passage of omega-3 fatty acids across the BBB	44
<i>Drugs that cross the BBB by binding to plasma proteins</i>	44
Current concepts of the permeability of the BBB	44
Factors that increase the permeability of the BBB	45
BBB disruption as an adverse effect of pharmaceuticals	45
BBB disruption as adverse effect of vaccines for CNS disorders	46
CNS disorders and BBB	46
Autoimmune disorders.....	47
Brain tumors	47
<i>Primary brain tumors</i>	47
<i>Cerebral metastases</i>	47
Central nervous system injuries.....	48
Cerebrovascular disease	48
<i>Cerebral ischemia</i>	48
<i>Intracerebral hemorrhage</i>	49
Epilepsy.....	49
Infections	49
Mitochondrial encephalopathies	50
Multiple sclerosis.....	50
Neurodegenerative disorders	51
<i>BBB in Alzheimer disease</i>	52
<i>BBB in Parkinson disease</i>	52
<i>BBB in amyotrophic lateral sclerosis</i>	53
West Nile virus infection	53
Testing permeability of the BBB.....	53
In vitro models of BBB.....	53
In vivo study of BBB.....	55
<i>Brain imaging</i>	55
In silico prediction of BBB	55
Relevance of the BBB penetration to pharmacological action	57
<i>BBB penetration and CNS drug screening</i>	57
<i>BBB models for testing drug delivery</i>	57
<i>CERENSESM</i>	58
<i>In vivo brain distribution of P-glycoprotein</i>	58
Transthyretin monomer as a marker of blood-CSF barrier disruption	58
Evaluation of BBB permeability by brain imaging	59
Biomarkers of disruption of blood-brain barrier	59
Future directions for research on the BBB	59
Use of neural stem cells to construct the blood brain barrier.....	60
Strategies to cross the BBB.....	60

3. Methods of Drug Delivery to the CNS

Introduction	62
Routes of drug delivery to the brain	63
Drug deliveries to the brain via the nasal route	63
<i>Devices for nasal administration of drugs for CNS</i>	65
<i>Nasal mucosal patch to facilitate drug delivery across the BBB</i>	65
<i>Passage of viruses to the brain via the nasal route</i>	65
<i>Potential and limitations of nasal drug delivery to the brain</i>	66
Drugs that can be delivered to the brain via the nasal route	66
<i>Erythropoietin</i>	66
<i>Esketamine</i>	66
<i>Hypocretin</i>	67
<i>IFN beta-1b</i>	67
<i>Lysosomal enzymes</i>	67
<i>Midazolam</i>	67
<i>Neurotrophic factors</i>	68
<i>Thyrotropin-releasing hormone</i>	68
<i>Neuroprotective drugs for stroke</i>	69
Transdermal drug delivery for neurological disorders	69
Drug delivery to the brain via inner ear	70
Drug delivery for disorders of the spinal cord.....	70
Intrathecal drug delivery.....	70
<i>Anatomical & physiological aspects of intrathecal drug delivery</i>	70
<i>Advantages of intrathecal drug delivery</i>	71
<i>Drugs that can be delivered by intrathecal route</i>	71
<i>Pharmacokinetics of intrathecal drug delivery</i>	72
<i>Retrograde delivery to the brain via the epidural venous system</i>	74
Devices for drug delivery to the CNS	74
<i>Catheters for drug delivery to the CNS</i>	74
<i>Reservoirs and pumps for drug delivery to the CNS</i>	75

Invasive neurosurgical approaches	76
<i>Intraarterial drug delivery to the brain</i>	76
<i>Direct injection into the CNS substance or CNS lesions</i>	76
<i>Targeted delivery of biologicals to the spinal cord by microinjection</i>	77
<i>Intraventricular injection of drugs</i>	77
Strategies for drug delivery to the CNS across the BBB	78
Increasing the permeability (opening) of the BBB	78
<i>Osmotic opening of the BBB</i>	78
<i>Focal disruption of BBB by ultrasound</i>	79
<i>Chemical opening of the BBB</i>	79
<i>Cerebral vasodilatation to open the BBB</i>	79
<i>Modulation of vascular permeability by laser irradiation</i>	80
<i>Neurostimulation for opening BBB</i>	80
<i>Use of nitric oxide donors to open the BBB</i>	81
<i>Manipulation of the sphingosine 1-phosphate receptor system</i>	81
Pharmacological strategies to facilitate transport across the BBB	81
<i>2B-Trans™ technology</i>	82
<i>ABC afflux transporters and penetration of the BBB</i>	82
<i>Adenosine agonist-mediated drug delivery across the BBB</i>	83
<i>Carrier-mediated drug delivery across the BBB</i>	83
<i>Fusion of receptor-binding peptide from apoE with therapeutic protein</i>	84
<i>G-Technology®</i>	84
<i>Glycosylation Independent Lysosomal Targeting</i>	85
<i>Inhibition of P-glycoprotein to enhance drug delivery across the BBB</i>	85
<i>LipoBridge™ technology</i>	86
<i>Modification of the drug to enhance its lipid solubility</i>	86
<i>Monoclonal antibody fusion proteins</i>	86
<i>Neuroimmunophilins</i>	87
<i>Peptide-mediated transport across the BBB</i>	87
<i>Prodrug bioconversion strategies and their CNS selectivity</i>	89
<i>Transport of small molecules across the BBB</i>	90
<i>Transport across the BBB by short chain oligoglycerolipids</i>	90
<i>Transvascular delivery across the BBB</i>	90
<i>Trojan horse approach</i>	90
<i>Role of the transferrin-receptor system in CNS drug delivery</i>	91
<i>Use of receptor-mediated transcytosis to cross the BBB</i>	91
Cell-based drug delivery to the CNS	93
<i>Activated T lymphocytes</i>	93
<i>Microglial cells</i>	94
<i>Neural stem cells</i>	94
Drug delivery to the CNS by using novel formulations.....	94
<i>Crystalline formulations</i>	94
<i>Liposomes</i>	94
<i>Monoclonal antibodies</i>	96
<i>Microspheres</i>	96
<i>Microbeads</i>	97
Brain-targeted chemical delivery systems	97
Nanotechnology-based drug delivery to CNS	98
Nanoparticles for drug delivery across the BBB	98
<i>NanoDel™ technology for crossing the BBB</i>	99
<i>Masking BBB-limiting characteristics by nanotechnology</i>	99
<i>Nanovesicles for transport across BBB</i>	99
<i>Peptide-nanoparticle conjugates for crossing the BBB</i>	99
<i>Penetration of BBB by nanoparticles coated with polysorbate 80</i>	100
<i>Targeting nicotinic acetylcholine receptor</i>	100
<i>Transcytosis of transferrin-containing nanoparticles across the BBB</i>	100
Nanotechnology-based devices and implants for CNS	101
Biochip implants for drug delivery to the CNS.....	101
Controlled-release microchip	101
Retinal implant chip	101
Convection-enhanced delivery to the CNS	102
Systemic administration of drugs for CNS effects	103
Sustained and controlled release drug delivery to the CNS	103
<i>Fast dissolving oral selegiline</i>	104
Choice of the route of systemic delivery for effect on the CNS disorders	105
Methods of delivery of biopharmaceuticals to the CNS	105
Delivery of biopharmaceuticals across the BBB	105
Methods of delivery of peptides for CNS disorders	106
<i>Alteration of properties of the BBB for delivery of peptides</i>	106
<i>Challenges for delivery of peptides across the BBB</i>	106
<i>CNS delivery of peptides via conjugation to biological carriers</i>	106

<i>Delivery of conopeptides to the brain</i>	107
<i>Direct delivery of neuropeptides into the brain</i>	107
<i>Molecular manipulations of peptides to facilitate transport into CNS</i>	108
<i>Transport to spinal cord motor neurons after peripheral injection</i>	108
<i>Transnasal administration of neuropeptides</i>	108
Delivery of neurotrophic factors to the nervous system.....	109
<i>Systemic administration of NTFs</i>	111
<i>Delivery systems to facilitate crossing of the BBB by NTFs</i>	111
<i>Direct application of NTFs to the CNS</i>	112
<i>Intracerebroventricular injection</i>	112
<i>Intrathecal administration</i>	113
<i>Implants for delivery of neurotrophic factors</i>	113
<i>Use of neurotrophic factor mimics</i>	114
<i>Use of microspheres for delivery of neurotrophic factors</i>	115
<i>Use of nanobiotechnology for delivery of neurotrophic factors</i>	115
Use of microorganisms for therapeutic entry into the brain	116
Bacteriophages as CNS therapeutics.....	116
Intracellular drug delivery in the brain	116
Local factors in the brain affecting drug action	117
Methods for testing drug delivery to the CNS	117
Animal models for testing drug delivery	117
Screening for drug-P-gp interaction at BBB	117
4. Delivery of Cell, Gene and Antisense Therapies to the CNS	120
Introduction	120
Cell therapy of neurological disorders	120
Methods for delivering cell therapies in CNS disorders	120
<i>Cerebrospinal fluid-stem cell interactions for therapy of CNS disorders</i>	121
<i>Engineered stem cells for drug delivery to the brain</i>	121
<i>Encapsulated cells</i>	122
<i>Intrathecal delivery of stem cells</i>	122
<i>Intraparenchymal delivery of stem cells to the spinal cord</i>	123
<i>Intravascular administration</i>	123
<i>Neural stem cells as therapeutic delivery vehicles</i>	124
Gene therapy techniques for the nervous system	124
Introduction	124
Methods of gene transfer to the nervous system	126
AAV vector mediated gene therapy for neurogenetic disorders.....	126
Ideal vector for gene therapy of neurological disorders	126
Promoters of gene transfer.....	127
Routes of delivery of genes to the nervous system.....	127
<i>Direct injection into CNS</i>	127
<i>Introduction of the genes into cerebral circulation</i>	128
<i>Introduction of genes into cerebrospinal fluid</i>	128
<i>Intravenous administration of vectors</i>	129
<i>Delivery of gene therapy to the peripheral nervous system</i>	129
Cell-mediated gene therapy of neurological disorders	129
<i>Neuronal cells</i>	129
<i>Neural stem cells and progenitor cells</i>	129
<i>Astrocytes</i>	130
<i>Cerebral endothelial cells</i>	130
<i>Implantation of genetically modified encapsulated cells into the brain</i>	130
<i>Genetically modified bone marrow cells</i>	130
Nanoparticles as nonviral vectors for CNS gene therapy.....	131
Applications of gene therapy for neurological disorders.....	131
Companies involved in cell/gene therapy of neurological disorders	132
Antisense therapy of CNS disorders	133
Delivery of antisense oligonucleotides to the CNS	134
Delivery of oligonucleotides cross the BBB	135
Cellular delivery systems for oligonucleotides	136
High-flow microinfusion into the brain parenchyma	136
Systemic administration of peptide nucleic acids.....	136
Introduction of antisense compounds into the CSF Pathways	137
Intrathecal administration of antisense compounds	137
Intracerebroventricular administration of antisense oligonucleotides.....	137
Nanoparticle-based delivery of antisense therapy to the CNS.....	138
Methods of delivery of ribozymes	138
Delivery aspects of RNAi therapy of CNS disorders	139
Delivery of siRNA to the CNS	139
Future drug delivery strategies applicable to the CNS	140

5. Drug Delivery for Treatment of Neurological Disorders	142
Introduction	142
Targeted drug delivery for neurological disorders	142
Parkinson's disease	142
Drug delivery systems for Parkinson's disease	144
<i>Methods of delivery of levodopa in PD</i>	<i>145</i>
<i>Duodenal levodopa infusion.....</i>	<i>145</i>
<i>Sublingual apomorphine</i>	<i>146</i>
<i>Transdermal drug delivery for PD.....</i>	<i>146</i>
<i>Transdermal dopamine agonists for PD</i>	<i>146</i>
<i>Transdermal administration of other drugs for PD</i>	<i>148</i>
<i>Intracerebral administration of GDNF</i>	<i>148</i>
Cell therapy for PD.....	148
<i>Human dopaminergic neurons for PD.....</i>	<i>149</i>
<i>Graft survival-enhancing drugs.....</i>	<i>150</i>
<i>Xenografting porcine fetal neurons.....</i>	<i>150</i>
<i>Encapsulated cells for PD</i>	<i>151</i>
<i>Stem cells for PD</i>	<i>151</i>
<i>Engineered stem cells for drug delivery to the brain in PD.....</i>	<i>152</i>
<i>Human retinal pigment epithelium cells for PD.....</i>	<i>153</i>
<i>Delivery of cells for PD.....</i>	<i>153</i>
Gene therapy for Parkinson disease.....	154
<i>Rationale</i>	<i>154</i>
<i>Techniques of gene therapy for PD.....</i>	<i>155</i>
<i>Prospects of gene therapy for PD</i>	<i>158</i>
<i>Companies developing gene therapy for PD.....</i>	<i>159</i>
RNAi therapy of Parkinson's disease	159
Alzheimer disease.....	160
Drug delivery for Alzheimer disease	160
Blood-brain partitioning of an AMPA receptor modulator	161
Clearing amyloid through the BBB.....	162
Delivery of the passive antibody directly to the brain.....	162
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	162
Nanoparticle-based drug delivery for Alzheimer's disease.....	162
Perispinal etanercept.....	163
Slow release implant of an AChE inhibitor	164
Intranasal insulin in Alzheimer disease	164
Transdermal drug delivery in Alzheimer's disease.....	164
Trojan-horse approach to prevent build-up of A β aggregates.....	165
Cell and gene therapy for Alzheimer disease.....	165
<i>NGF gene therapy.....</i>	<i>165</i>
<i>Neprilysin gene therapy</i>	<i>166</i>
RNAi therapy of Alzheimer's disease	167
Huntington's disease	167
Treatment of HD	167
Gene therapy of HD	168
<i>Encapsulated genetically engineered cellular implants.....</i>	<i>168</i>
<i>Viral vector mediated administration of neurotrophic factors</i>	<i>168</i>
<i>RNAi therapeutics for the treatment of HD</i>	<i>168</i>
Amyotrophic lateral sclerosis.....	169
Treatment of ALS.....	169
Drug delivery in ALS.....	169
Delivery of stem cell therapy for ALS.....	170
Gene and antisense therapy of ALS	171
<i>Neurotrophic factor gene therapies of ALS.....</i>	<i>171</i>
<i>Antisense therapy of ALS</i>	<i>173</i>
<i>RNAi therapy of amyotrophic lateral sclerosis</i>	<i>173</i>
Cerebrovascular disease	173
Treatment of stroke	174
Drug delivery in stroke	174
<i>Intraarterial administration of tissue plasminogen activator in stroke.....</i>	<i>175</i>
Drug delivery for prevention of restenosis of carotid arteries	176
<i>In-stent restenosis.....</i>	<i>176</i>
<i>Targeted local anti-restenotic drug delivery.....</i>	<i>177</i>
<i>Catheter-based drug delivery for restenosis</i>	<i>177</i>
<i>Stents for prevention of restenosis.....</i>	<i>178</i>
<i>Drug-eluting stents</i>	<i>178</i>
<i>Antisense approach to prevent restenosis</i>	<i>179</i>
Drug-eluting stents for the treatment of intracranial atherosclerosis.....	179
Tissues transplants for stroke.....	180
<i>Transplant of encapsulated tissue secreting neurotrophic factors</i>	<i>180</i>

Methods for delivery of neurotrophic factors in stroke.....	180
Cell therapy for stroke.....	180
<i>Stem cell transplant into the brain</i>	181
<i>Immortalized cell grafts for stroke</i>	181
<i>Intravenous infusion of marrow stromal cells</i>	182
<i>Intravenous infusion of umbilical cord blood stem cells</i>	182
<i>Future of cell therapy for stroke</i>	182
Gene therapy of cerebrovascular diseases.....	182
<i>Gene transfer to cerebral blood vessels</i>	183
<i>NOS gene therapy for restenosis</i>	184
Gene therapy for cerebral ischemia.....	184
<i>Gene therapy of strokes with a genetic component</i>	186
Drug delivery to intracranial aneurysms.....	186
Drug delivery for vasospasm following subarachnoid hemorrhage.....	186
<i>Intrathecal tissue plasminogen activator</i>	187
<i>Gene therapy for vasospasm</i>	188
Drug delivery in multiple sclerosis.....	189
An electronic device for self injection of interferon beta-1a.....	189
Oral therapies for MS.....	189
Drug delivery for MS across the BBB.....	190
<i>Delivery of methylprednisolone across the BBB</i>	190
<i>Monoclonal antibodies for MS and the BBB</i>	190
Antisense and RNAi approaches to MS.....	190
Cell therapy for multiple sclerosis.....	191
<i>Hematopoietic stem cell transplantation for multiple sclerosis</i>	191
<i>Embryonic stem cells and neural precursor cells for MS</i>	192
Gene therapy for multiple sclerosis.....	192
Drug delivery in epilepsy.....	192
Routes of administration of antiepileptic drugs.....	193
<i>Controlled-release preparations of carbamazepine</i>	193
<i>Intravenous carbamazepine</i>	193
<i>Various routes of administration of benzodiazepines</i>	194
Methods of delivery of novel antiepileptic therapies.....	194
<i>Regulated activation of prodrugs</i>	194
<i>Use of neuronal membrane transporter</i>	194
<i>Delivery of the antiepileptic conopeptides to the brain</i>	195
<i>Nasal administration of AEDs</i>	195
<i>Intracerebral administration of AEDs</i>	195
The role of drug delivery in status epilepticus.....	196
Cell therapy of epilepsy.....	197
Gene therapy for epilepsy.....	197
<i>Gene therapy for neuroprotection in epilepsy</i>	198
Concluding remarks on drug delivery in epilepsy.....	198
Drug delivery for pain.....	199
Intranasal delivery of analgesics.....	200
<i>Intranasal administration of morphine</i>	200
<i>Intranasal morphine derivatives</i>	200
<i>Intranasal fentanyl</i>	201
<i>Intranasal buprenorphine</i>	202
<i>Intranasal ketamine</i>	202
<i>Intranasal ketorolac</i>	202
Delivery of analgesics by inhalation.....	202
Delivery of analgesics to peripheral nerves.....	203
Spinal delivery of analgesics.....	204
<i>Epidural dexamethasone</i>	206
<i>Epidural morphine</i>	206
<i>Relief of pain by intrathecal ziconotide</i>	206
<i>Intrathecal neostigmine</i>	207
<i>Intrathecal prostaglandin antagonists</i>	207
<i>Intrathecal fadolmidine</i>	207
<i>Intrathecal siRNA for relief of neuropathic pain</i>	208
<i>Concluding remarks on intrathecal delivery of analgesic agents</i>	208
Intracerebroventricular drug delivery for pain.....	208
<i>Delivery of analgesics to the CNS across the BBB</i>	208
Drug delivery for migraine.....	209
Management of migraine.....	209
Novel drug delivery methods for migraine.....	210
<i>Nasal formulations for migraine</i>	211
<i>Sublingual spray for migraine</i>	211
<i>Needle-free drug delivery for migraine</i>	212
Drug delivery for traumatic brain injury.....	212

Cell therapy of traumatic brain injury	212
<i>Gene therapy for traumatic brain injury</i>	213
Drug delivery for spinal cord injury	213
Administration of neurotrophic factors for spinal cord injury	213
Cell therapy for spinal cord injury	214
<i>Transplantation of glial cells for SCI</i>	214
<i>Fetal neural grafts for SCI</i>	214
<i>Embryonic stem cells for SCI</i>	214
<i>Schwann cell transplants for SCI</i>	215
<i>Olfactory glial cells for SCI</i>	215
<i>Marrow stromal cells for SCI</i>	216
<i>Intravenous injection of stem cells for spinal cord repair</i>	216
<i>Combinatorial approach for regeneration in SCI</i>	216
<i>Cell therapy of syringomyelia</i>	217
<i>Gene therapy of spinal cord injury</i>	217
Drug delivery in CNS infections.....	217
Drug delivery in neuroAIDS	218
Drug delivery for miscellaneous neurological disorders.....	218
Drug delivery for CNS involvement in Hunter syndrome	218
Antisense therapy for spinal muscular atrophy.....	219
<i>Antisense gene splicing for SMA</i>	219
<i>Intrathecal antisense delivery</i>	219
Genetically modified stem cells for metachromatic leukodystrophy	219
Relief of spasticity by intrathecal baclofen	220
Drug delivery for retinal disorders.....	220
<i>Age-related macular degeneration</i>	220
<i>Squalamine</i>	221
<i>Combretastatin A4P for myopic macular degeneration</i>	221
<i>Gene therapy for AMD</i>	221
<i>Anti-VEGF approach to AMD</i>	222
<i>Delivery of pegaptanib for treatment of AMD</i>	222
Stem cell therapy for retinitis pigmentosa	222
Proliferative retinopathies	223
Drug delivery for inner ear disorders	223
Delivery of stem cells for hearing loss.....	224
Auditory hair cell replacement by gene therapy	224
Future prospects of drug delivery to the inner ear	224
Drug delivery in psychiatric disorders.....	225
Delivery of antidepressants	225
<i>Transdermal delivery of antidepressants</i>	226
<i>Nasal delivery of antidepressants</i>	228
Delivery methods and formulations of antipsychotics	228
<i>Long-acting injectable antipsychotics</i>	228
<i>Transdermal haloperidol</i>	229
<i>Transdermal risperidone for treatment of schizophrenia</i>	229
<i>Transdermal blonanserin for treatment of schizophrenia</i>	230
<i>Transnasal oxytocin for schizophrenia</i>	230
Transdermal lithium for bipolar disorder	230
6. Drug delivery for brain tumors	232
Introduction	232
Methods for evaluation of anticancer drug penetration into brain tumor	232
Innovative methods of drug delivery for glioblastoma multiforme.....	232
Delivery of anticancer drugs across the blood-brain barrier	233
Anticancer agents with increased penetration of BBB.....	233
BBB disruption.....	234
Nanoparticle-based targeted delivery of chemotherapy across the BBB	235
Tyrosine kinase inhibitor increases topotecan penetration into CNS	236
Bypassing the BBB by alternative methods of drug delivery	237
Intranasal perillyl alcohol	237
Intraarterial chemotherapy	237
Enhancing tumor permeability to chemotherapy	238
PDE5 inhibitors for increasing BTB permeability	238
Local delivery of therapeutic agents into the brain	238
Biodegradable microspheres containing 5-FU.....	238
Carmustine biodegradable polymer implants	239
Fibrin glue implants containing anticancer drugs	240
Interstitial delivery of dexamethasone for reduction of peritumor edema	240
Magnetically controlled microspheres.....	240
Convection-enhanced delivery	240
CED for receptor-directed cytotoxin therapy	240

CED of topotecan	241
CED of a modified diphtheria toxin conjugated to transferrin	241
CED of nanoliposomal CPT-11.....	241
CED for delivery ¹³¹ I-chTNT-1/B MAb	242
Anticancer drug formulations for targeted delivery to brain tumors	242
Intravenous delivery of anticancer agents bearing transferrin	242
Liposomes for drug delivery to brain tumors.....	242
MAbs targeted to brain tumors	243
Targeted delivery of drug-peptide conjugates to GBM.....	243
Multiple targeted drugs for brain tumors	244
Nanoparticles for targeted drug delivery in glioblastoma multiforme	244
Targeted antiangiogenic/apoptotic/cytotoxic therapies.....	245
Targeted drug delivery to gliomas using cholera toxin subunit B	246
Introduction of the chemotherapeutic agent into the CSF pathways	246
Intraventricular chemotherapy for meningeal cancer	246
Intrathecal chemotherapy	247
Photodynamic therapy for chemosensitization of brain tumors	247
Nanoparticles for photodynamic therapy of brain tumors.....	248
Innovative delivery of radiotherapy to brain tumors	248
GliaSite Radiation Therapy System.....	248
Boron neutron capture therapy for brain tumors	248
Cell therapy for glioblastoma multiforme.....	249
Chimeric antigen receptor T cells	249
Mesenchymal stem cells to deliver treatment for gliomas.....	249
Gene therapy for glioblastoma multiforme.	249
Antiangiogenic gene therapy	251
Anticancer drug delivery by genetically engineered MSCs.....	251
Intravenous gene delivery with nanoparticles into brain tumors	251
Ligand-directed delivery of dsRNA molecules targeted to EGFR	252
Neural stem cells for drug/gene delivery to brain tumors	252
Peptides targeted to glial tumor cells.....	253
RNAi gene therapy of brain cancer	253
Single-chain antibody-targeted adenoviral vectors	253
Targeting normal brain cells with an AAV vector encoding interferon- β	254
Treatment of medulloblastoma by suppressing genes in Shh pathway	254
Virus-mediated oncolytic therapy of brain cancer	255
<i>HIV-mediated Oncolysis.....</i>	<i>255</i>
<i>Autophagy by conditionally replicating adenoviruses.....</i>	<i>255</i>
<i>Reovirus-mediated Oncolysis.....</i>	<i>256</i>
<i>Measles virus-mediated oncolysis.....</i>	<i>256</i>
<i>Oncolytic virus targeted to brain tumor stem cells.....</i>	<i>256</i>
<i>Oncolysis with vesicular stomatitis virus</i>	<i>257</i>
<i>Future prospects of viral-mediated oncolysis</i>	<i>257</i>
Vaccination for glioblastoma multiforme	257
7. Markets for Drug Delivery in CNS Disorders.....	258
Introduction	258
Methods of calculation of CNS drug delivery markets.....	258
Markets for CNS drug delivery technologies	258
Drug delivery share in selected CNS markets.....	259
CNS share of drug delivery technologies	259
Geographical distribution of CNS drug delivery markets.....	260
Impact of improved drug delivery on CNS drug markets.....	260
Neurodegenerative disorders.....	260
<i>Alzheimer disease</i>	<i>261</i>
<i>Parkinson disease</i>	<i>261</i>
<i>Huntington disease</i>	<i>261</i>
<i>Amyotrophic lateral sclerosis</i>	<i>261</i>
Epilepsy.....	262
Migraine and other headaches	262
Stroke	262
Central nervous system trauma	263
Multiple sclerosis.....	263
Brain tumors	263
Limitations of the current drug delivery technologies for CNS	264
Unmet needs in CNS drug delivery technologies	264
Future strategies for expanding CNS drug delivery markets.....	265
Education of neurologists	265
Demonstration of the advantages of the newer methods of delivery	266
Rescue of old products by novel drug delivery methods	266
Facilitation of the approval process of new drugs	266

8. Companies	268
Introduction	268
Profiles of companies	268
Collaborations	354
9. References	358

Tables

Table 1-1: Landmarks in the development of drug delivery to the CNS	18
Table 2-1: Proteins expressed at the neurovascular unit	31
Table 2-2: Transporters that control penetration of molecules across the BBB	36
Table 2-3: Enzymes that control the penetration of molecules across the BBB	40
Table 2-4: Factors that increase the permeability of the BBB.....	45
Table 2-5: Diseases with associated disturbances of BBB	46
Table 3-1: Various methods of drug delivery to the central nervous system	62
Table 3-2: Drugs available for intrathecal administration	72
Table 3-3: Investigational drugs administered by intrathecal route	72
Table 3-4: Strategies for drug delivery to the CNS across the BBB	78
Table 3-5: Specific inhibitors of P-glycoprotein in clinical development	85
Table 3-6: Molecules attached to Trojan horses injected intravenously for CNS effect.....	90
Table 3-7: Examples of controlled and sustained release drug delivery for CNS disorders	104
Table 3-8: Novel methods of delivery of drugs for CNS disorders	105
Table 3-9: Indications for the clinical applications of NTFs in neurologic disorders	109
Table 3-10: Methods for delivery of neurotrophic factors to the CNS	110
Table 4-1: Methods for delivering cell therapies in CNS disorders.....	121
Table 4-2: Classification of methods of gene therapy.....	125
Table 4-3: Methods of gene transfer as applied to neurologic disorders	126
Table 4-4: Potential indications for gene therapy of neurologic disorders	131
Table 4-5: Companies developing cell/gene therapies for CNS disorders	133
Table 4-6: Methods of antisense delivery as applied to the CNS.....	134
Table 5-1: Strategies for the treatment of Parkinson's disease	142
Table 5-2: Drug delivery systems for Parkinson's disease	144
Table 5-3: Types of cell used for investigative treatment of Parkinson's disease	149
Table 5-4: Status of cell therapies in development for Parkinson's disease	149
Table 5-5: Gene therapy techniques applicable to Parkinson disease	155
Table 5-6: Companies developing gene therapy for Parkinson's disease.....	159
Table 5-7: Classification of pharmacotherapy for Alzheimer disease	160
Table 5-8: Novel drug delivery methods for Alzheimer disease therapies	161
Table 5-9: Classification of neuroprotective agents for amyotrophic lateral sclerosis.....	169
Table 5-10: Methods of delivery of therapies in development for ALS	170
Table 5-11: Classification of treatments for stroke	174
Table 5-12: Treatments of stroke involving innovative drug delivery methods	175
Table 5-13: Drug delivery for prevention of carotid artery restenosis after angioplasty	177
Table 5-14: Gene transfer in animal models of carotid artery restenosis	183
Table 5-15: Neuroprotective gene transfer strategies in models of cerebral ischemia	184
Table 5-16: Gene Therapy for reducing cerebral infarction in animal stroke models.....	185
Table 5-17: Pharmacological agents for treatment of cerebral vasospasm.....	187
Table 5-18: Gene therapy strategies for vasospasm.....	188
Table 5-19: A classification of drug delivery methods used in management of pain	199
Table 5-20: Spinal administration of drugs for pain	204
Table 5-21: Investigational drugs for pain administered by intrathecal route	204
Table 5-22: Current management of migraine	209
Table 5-23: Novel drug delivery methods for migraine	210
Table 6-1: Innovative methods of drug delivery for glioblastoma multiforme	232
Table 6-2: Strategies for gene therapy of malignant brain tumors.....	250
Table 7-1: Share of drug delivery technologies in selected CNS markets: 2017-2027	259
Table 7-2: CNS market share of drug delivery technologies 2017-2027	259
Table 7-3: Value of CNS drug delivery in the major world markets from 2017-2027	260
Table 7-4: Limitations of the current drug delivery technologies for CNS.....	264
Table 8-1: Alkermes pipeline.....	275
Table 8-2: Collaborations of companies in CNS drug delivery	354

Figures

Figure 1-1: Interaction of neurotransmitters with receptors	22
Figure 2-1: The neurovascular unit	30
Figure 2-2: Various forms of passage of substances across the blood brain barrier.....	36
Figure 2-3: Role of BBB models for drug delivery in preclinical CNS drug development	58
Figure 3-1: Routes of drug delivery to the brain	63
Figure 3-2: Extracellular mechanism for drug transportation to the brain following intranasal administration.....	64
Figure 3-3: Penetration of CSF into spinal cord	71
Figure 3-4: Disposition of opioids after intrathecal administration	73
Figure 3-5: Use of receptor-mediated transcytosis to cross the BBB	92
Figure 3-6: Nanotechnology-based strategies for delivery of BDNF to the CNS	116
Figure 5-1: Oral versus transdermal administration of a drug in Parkinson's disease	147
Figure 5-2: Effect of tyrosine hydroxylase gene delivery on dopamine levels	156
Figure 6-1: A concept of targeted drug delivery to GBM across the BBB.....	235
Figure 7-1: Unmet needs in the CNS drug delivery technologies	265